- €771.69m
- €704.43m
- $376.13m
Brief: Pharming Group Expects 2026 Revenue At $405-$425 Mln
Brief: Pharming Group Says Co Receives Complete Response Letter From U.S. FDA For SNDA For Joenja (Leniolisib) In Children Aged 4 To 11 Years With Apds
Pharming shares rise 5% as 2025 preliminary revenue exceeds guidance
Brief: Pharming Group Projects 2025 Revenues Of $376 Mln, Ahead Of Guidance
Brief: Pharming Group Hikes FY Revenue Guidance To $365-375 Mln
Brief: Pharming Group 9M Operating Profit USD 19.6 Million
Brief: Pharming Group Anticipates $7 Mln Restructuring Costs In Q4
FDA Acceptance, Priority Review For Leniolisib In Children With APDS
Brief: Euronext Expands Amsterdam's AEX Index To 30 Constituents As Of Sept. 22
Brief: Pharming Group Appoints Kenneth Lynard As New CFO
Brief: Pharming Group H1 Gross Profit USD 155 Million
Brief: Pharming Group Doses First Patient In Phase II CVID Trial
Pharming Group NV reports results for the quarter ended December 31 - Earnings Summary
Brief: Pharming Group FY Net Loss At $11 Million
Pharming Group NV expected to post earnings of 1 cent a share - Earnings Preview
Brief: Pharming Technologies B.V. Increases Its Ownership In Abliva AB (Publ) To 92.70 Percent
Brief: Pharming Group To Nominate Fabrice Chouraqui As New CEO
Europe Research Roundup: Ashtead Technology Holdings, Hugo Boss, Pernod Ricard
Brief: Pharming Group NV Offers SEK 0.45 Per Share In Abliva, Deal Valued At $66.1 Million